Clinical Trial Detail

NCT ID NCT03819465
Title A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors AstraZeneca
Indications

non-small cell lung carcinoma

Therapies

Gemcitabine

Durvalumab + Oleclumab

Carboplatin

Pemetrexed

nab-paclitaxel

AZD9150 + Durvalumab

Cisplatin

Durvalumab

Age Groups: senior adult

No variant requirements are available.